Literature DB >> 11489614

Effect of ketamine on the neuromagnetic mismatch field in healthy humans.

I Kreitschmann-Andermahr1, T Rosburg, U Demme, E Gaser, H Nowak, H Sauer.   

Abstract

Mismatch negativity (MMN) is a component of the auditory evoked event-related potentials (ERP) that assesses automatic sound change detection and is disturbed in schizophrenic patients. Animal experimental evidence has linked the generation of MMN to the N-methyl-D-aspartate (NMDA) receptor. We investigated the neuromagnetic mismatch field (MMF) in healthy volunteers before and after intravenous application of a subanesthetic dose of the NMDA receptor antagonist ketamine (0.3 mg/kg). Ketamine had a significant influence on latency and dipole moment of the MMF, whereas the N100m latency of the standard tone was not prolonged and its dipole moment remained stable. Our results suggest that ketamine interferes with aspects of preattentive information processing and is in line with the view that disturbed NMDA receptor function may mediate the deficient auditory mismatch response in patients with schizophrenia.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11489614     DOI: 10.1016/s0926-6410(01)00043-x

Source DB:  PubMed          Journal:  Brain Res Cogn Brain Res        ISSN: 0926-6410


  49 in total

Review 1.  How human electrophysiology informs psychopharmacology: from bottom-up driven processing to top-down control.

Authors:  J Leon Kenemans; Seppo Kähkönen
Journal:  Neuropsychopharmacology       Date:  2010-10-06       Impact factor: 7.853

Review 2.  Translating glutamate: from pathophysiology to treatment.

Authors:  Daniel C Javitt; Darryle Schoepp; Peter W Kalivas; Nora D Volkow; Carlos Zarate; Kalpana Merchant; Mark F Bear; Daniel Umbricht; Mihaly Hajos; William Z Potter; Chi-Ming Lee
Journal:  Sci Transl Med       Date:  2011-09-28       Impact factor: 17.956

Review 3.  Neurophysiological models for new treatment development in schizophrenia: early sensory approaches.

Authors:  Daniel C Javitt
Journal:  Ann N Y Acad Sci       Date:  2015-02-26       Impact factor: 5.691

4.  Interactive effects of an N-methyl-d-aspartate receptor antagonist and a nicotinic acetylcholine receptor agonist on mismatch negativity: Implications for schizophrenia.

Authors:  Holly K Hamilton; Deepak C D'Souza; Judith M Ford; Brian J Roach; Naomi S Kort; Kyung-Heup Ahn; Savita Bhakta; Mohini Ranganathan; Daniel H Mathalon
Journal:  Schizophr Res       Date:  2017-07-12       Impact factor: 4.939

5.  Modeling ketamine effects on synaptic plasticity during the mismatch negativity.

Authors:  André Schmidt; Andreea O Diaconescu; Michael Kometer; Karl J Friston; Klaas E Stephan; Franz X Vollenweider
Journal:  Cereb Cortex       Date:  2012-08-08       Impact factor: 5.357

6.  Acute dopamine and/or serotonin depletion does not modulate mismatch negativity (MMN) in healthy human participants.

Authors:  Sumie Leung; Rodney J Croft; Valérie Guille; Kirsty Scholes; Barry V O'Neill; K Luan Phan; Pradeep J Nathan
Journal:  Psychopharmacology (Berl)       Date:  2009-12-10       Impact factor: 4.530

Review 7.  Auditory dysfunction in schizophrenia: integrating clinical and basic features.

Authors:  Daniel C Javitt; Robert A Sweet
Journal:  Nat Rev Neurosci       Date:  2015-09       Impact factor: 34.870

Review 8.  Sensory processing in schizophrenia: neither simple nor intact.

Authors:  Daniel C Javitt
Journal:  Schizophr Bull       Date:  2009-10-15       Impact factor: 9.306

9.  Somatosensory system deficits in schizophrenia revealed by MEG during a median-nerve oddball task.

Authors:  Ming-Xiong Huang; Roland R Lee; Kathleen M Gaa; Tao Song; Deborah L Harrington; Cathy Loh; Rebecca J Theilmann; J Christopher Edgar; Gregory A Miller; Jose M Canive; Eric Granholm
Journal:  Brain Topogr       Date:  2009-11-27       Impact factor: 3.020

10.  Mismatch negativity generation in the human 5HT2A agonist and NMDA antagonist model of psychosis.

Authors:  Karsten Heekeren; Jörg Daumann; Anna Neukirch; Carsten Stock; Wolfram Kawohl; Christine Norra; Till D Waberski; Euphrosyne Gouzoulis-Mayfrank
Journal:  Psychopharmacology (Berl)       Date:  2008-05-18       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.